News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

U3 Pharma Achieves Preclinical Proof of Concept for U3-1287 (AMG 888)


4/14/2008 9:28:05 AM

MUNICH, Germany--(BUSINESS WIRE)--U3 Pharma, a translational medicine-focused oncology company, today announced that preclinical proof-of-concept has been established for its lead product U3-1287 (AMG 888), the first fully human anti-HER3 monoclonal antibody (mAb). In vitro and in vivo studies of U3-1287 (AMG 888), which is being developed in partnership with Amgen, demonstrate that the antibody inhibits oncogenic signaling and proliferation of tumors. The results from these studies will be presented in two posters at the American Association for Cancer Research Annual Meeting in San Diego, California on April 13, 2008.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES